Temozolomide (CCRG 81045)

Name: Temozolomide (CCRG 81045)
Brand: Selleck Chemicals
SKU: S1237
Rating: 5 (113 reviews)

For research use only.

Catalog No.S1237 Synonyms: NSC 362856,TMZ

113 publications

Temozolomide (CCRG 81045) Chemical Structure

CAS No. 85622-93-1

Temozolomide (CCRG81045, NSC 362856, TMZ) is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells. Temozolomide induces apoptosis and exhibits antitumor activity.

Selleck's Temozolomide (CCRG 81045) has been cited by 113 publications

Cell Res, 2021, 10.1038/s41422-021-00528-3

PubMed: 34239070 ( click the link to review the publication )

Nature, 2020, 580(7804):517-523.

PubMed: 32322066 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Theranostics, 2021, 11(4):1991-2005

PubMed: 33408794 ( click the link to review the publication )

J Exp Clin Cancer Res, 2021, 40(1):164

PubMed: 33975615 ( click the link to review the publication )

Front Cell Dev Biol, 2021, 9:683038

PubMed: 34195200 ( click the link to review the publication )

Hum Mol Genet, 2021, ddab009

PubMed: 33438023 ( click the link to review the publication )

Front Oncol, 2021, 11:635472

PubMed: 33718225 ( click the link to review the publication )

Front Oncol, 2021, 11:638802

PubMed: 33869025 ( click the link to review the publication )

Cancer Gene Ther, 2021, 10.1038/s41417-021-00353-1

PubMed: 34059782 ( click the link to review the publication )

Neurochem Int, 2021, 147:105051

PubMed: 33979572 ( click the link to review the publication )

Phytother Res, 2021, 10.1002/ptr.7061

PubMed: 33856743 ( click the link to review the publication )

Mol Med, 2021, 27(1):28

PubMed: 33765907 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2021, 10.1007/s00432-021-03678-4

PubMed: 34085099 ( click the link to review the publication )

Exp Ther Med, 2021, 21(2):175

PubMed: 33456542 ( click the link to review the publication )

Autophagy, 2021, 1-15

PubMed: 33629929 ( click the link to review the publication )

Oncol Rep, 2021, 45(4)34

PubMed: 33649855 ( click the link to review the publication )

J Clin Invest, 2020, 134132

PubMed: 33016930 ( click the link to review the publication )

Nat Commun, 2020, 11(1):550

PubMed: 31992716 ( click the link to review the publication )

J Clin Invest, 2020, 139542

PubMed: 33332283 ( click the link to review the publication )

J Thorac Oncol, 2020, 10.1016/j.jtho.2020.01.012

PubMed: 32004714 ( click the link to review the publication )

Clin Cancer Res, 2020, clincanres.2585.2020

PubMed: 33229458 ( click the link to review the publication )

Oncogene, 2020, 5

PubMed: 32372061 ( click the link to review the publication )

EBioMedicine, 2020, 59:102971

PubMed: 32846370 ( click the link to review the publication )
Cell Death Dis, 2020, 11(10):890

PubMed: 33087705 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 22;5(1):44

PubMed: 32317623 ( click the link to review the publication )

Cell Chem Biol, 2020, S2451-9456(20)30384-6

PubMed: 33113406 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(10):2001-2011

PubMed: 32737157 ( click the link to review the publication )

Aging (Albany NY), 2020, 29;12(2):1685-1703

PubMed: 32003751 ( click the link to review the publication )

Neuroendocrinology, 2020, 3

PubMed: 32241015 ( click the link to review the publication )

Mater Sci Eng C Mater Biol Appl, 2020, 108:110191

PubMed: 31923988 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.15114

PubMed: 32150671 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(21)E8353

PubMed: 33171763 ( click the link to review the publication )

Sci Rep, 2020, 10(1):3836

PubMed: 32123273 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Front Neurosci, 2020, 14:598266

PubMed: 33328869 ( click the link to review the publication )

Fluids Barriers CNS, 2020, 2;17(1):37

PubMed: 32487241 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2020, 146(7):1659-1670

PubMed: 32279088 ( click the link to review the publication )

Transl Oncol, 2020, 13(1):70-78

PubMed: 31810002 ( click the link to review the publication )

PLoS One, 2020, 22;15(4):e0231470

PubMed: 32320427 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Cancer Res, 2020, canres.132.2020

PubMed: 32680921 ( click the link to review the publication )

Cell Signal, 2020, 71:109598

PubMed: 32165236 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 39(1):137

PubMed: 32677981 ( click the link to review the publication )

Cancer Cell Int, 2020, 20:71

PubMed: 32165861 ( click the link to review the publication )

Theranostics, 2020, 10(7):3351-3365

PubMed: 32194873 ( click the link to review the publication )

Cancer Cell Int, 2020, 20:65

PubMed: 32158355 ( click the link to review the publication )
Nat Commun, 2019, 10(1):4529

PubMed: 31586101 ( click the link to review the publication )

J Pineal Res, 2019, 66(3):e12556

PubMed: 30648757 ( click the link to review the publication )

Autophagy, 2019, 15(6):1100-1111

PubMed: 30654687 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)

PubMed: 31810230 ( click the link to review the publication )

Cell Death Dis, 2019, 10(12):881

PubMed: 31754113 ( click the link to review the publication )

FASEB J, 2019, 33(12):13476-13491

PubMed: 31570001 ( click the link to review the publication )

Hum Mol Genet, 2019, 28(16):2738-2751

PubMed: 31087038 ( click the link to review the publication )

Hum Mol Genet, 2019, 10.1093/hmg/ddz152

PubMed: 31518391 ( click the link to review the publication )

Eur J Pharm Biopharm, 2019, 136:156-163

PubMed: 30682492 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(3):606-617

PubMed: 31565489 ( click the link to review the publication )

Endocrinology, 2019, 160(11):2600-2617

PubMed: 31322702 ( click the link to review the publication )

Cancer Commun (Lond), 2019, 39(1):81

PubMed: 31796105 ( click the link to review the publication )

Eur J Pharmacol, 2019, 852:42-50

PubMed: 30851271 ( click the link to review the publication )

J Oncol, 2019, 2019:1805841

PubMed: 31275377 ( click the link to review the publication )

Oncol Lett, 2019, 18(3):2509-2517

PubMed: 31402948 ( click the link to review the publication )

Anticancer Res, 2019, 39(12):6731-6741

PubMed: 31810938 ( click the link to review the publication )

Mol Imaging, 2019, 18:1536012119870899

PubMed: 31478435 ( click the link to review the publication )

Pharmaceutics, 2019, 11(8)E401

PubMed: 31405159 ( click the link to review the publication )

Nat Cell Biol, 2018, 20(10):1203-1214

PubMed: 30202050 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):446-462

PubMed: 29202477 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2494

PubMed: 29950602 ( click the link to review the publication )

Genome Res, 2018, 28(8):1207-1216

PubMed: 29898900 ( click the link to review the publication )

Cancer Res, 2018, 78(23):6632-6642

PubMed: 30322863 ( click the link to review the publication )

J Control Release, 2018, 269:245-257

PubMed: 29162480 ( click the link to review the publication )
J Hematol Oncol, 2018, 11(1):32

PubMed: 29486795 ( click the link to review the publication )

Cancer Lett, 2018, 433:210-220

PubMed: 30008386 ( click the link to review the publication )

Mol Pharm, 2018, 15(2):609-618

PubMed: 29308904 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(5):777-790

PubMed: 29431617 ( click the link to review the publication )

Sci Rep, 2018, 8(1):7222

PubMed: 29740146 ( click the link to review the publication )

Int J Oncol, 2018, 52(1):295-304

PubMed: 29115581 ( click the link to review the publication )

Cell Cycle, 2018, 17(10):1199-1211

PubMed: 29886801 ( click the link to review the publication )

Cancer Med, 2018, 7(4):1404-1415

PubMed: 29479863 ( click the link to review the publication )

J Pharm Sci, 2018, 107(3):922-933

PubMed: 29162424 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:7031-7040

PubMed: 30410360 ( click the link to review the publication )

Oncol Lett, 2018, 16(5):5607-5614

PubMed: 30344715 ( click the link to review the publication )

Medicines (Basel), 2018, 5(2)

PubMed: 29925764 ( click the link to review the publication )

J Neurooncol, 2018,

PubMed: 29564747 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(2):523-535

PubMed: 27440269 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(20):6239-6253

PubMed: 28698200 ( click the link to review the publication )

Neuro Oncol, 2017, 20(2):236-248

PubMed: 29016925 ( click the link to review the publication )

Cell Syst, 2017, 4(6-:600-610

PubMed: 28601558 ( click the link to review the publication )

Cancer Lett, 2017, 386:131-140

PubMed: 27894958 ( click the link to review the publication )

Cell Death Dis, 2017, 8(10):e3062

PubMed: 28981092 ( click the link to review the publication )

Mol Oncol, 2017, 11(2):180-193

PubMed: 28098415 ( click the link to review the publication )

Hum Mol Genet, 2017, 26(22):4375-4387

PubMed: 28973155 ( click the link to review the publication )

Eur J Med Chem, 2017, 127:691-702

PubMed: 27823879 ( click the link to review the publication )

Oncotarget, 2017, 8(12):18626-18639

PubMed: 28148893 ( click the link to review the publication )

Oncotarget, 2017, 8(18):29865-29886

PubMed: 28415741 ( click the link to review the publication )
Cell Stem Cell, 2017, 20(2):233-246

PubMed: 27989769 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2017, 1861(9):2282-2292

PubMed: 28687190 ( click the link to review the publication )

JCI Insight, 2017, 2(24)

PubMed: 29263302 ( click the link to review the publication )

J Clin Invest, 2016, 126(5):1801-14

PubMed: 27043280 ( click the link to review the publication )

Cancer Res, 2016, 76(1):139-49

PubMed: 26542214 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(10):2302-2313

PubMed: 27474148 ( click the link to review the publication )

Eur J Pharm Biopharm, 2016, 104:7-18

PubMed: 27106606 ( click the link to review the publication )

Neurochem Res, 2016, 41(12):3192-3205

PubMed: 27632183 ( click the link to review the publication )

Oncotarget, 2016, 7(27):41251-41264

PubMed: 27183910 ( click the link to review the publication )

Oncotarget, 2016, 7(43):69961-69975

PubMed: 27564106 ( click the link to review the publication )

Oncotarget, 2016, 7(48):79869-79884

PubMed: 27829215 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):11443-56

PubMed: 27006309 ( click the link to review the publication )

Radiother Oncol, 2015, 116(3):467-72

PubMed: 26163089 ( click the link to review the publication )

PLoS One, 2015, 10(11):e0142704

PubMed: 26571493 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(6):1555-65

PubMed: 24501391 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(12):1646-57

PubMed: 25482938 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(7):1740-7

PubMed: 23406775 ( click the link to review the publication )

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description

Features

Methazolastone is a second-generation alkylating agent.

Targets

DNA replication ^[1]
(L-1210, L-1210/BCNU cells)

In vitro

Methazolastone causes formation of DNA alkali-labile sites which are present in similar amounts and repaired at a similar rate in L-1210 and L-1210/BCNU cell lines. In L-1210 but not in L-1210/BCNU methazolastone induces an arrest of cells in SL-G2-M phases.^[1] Methazolastone sensitivity of both chemo-sensitive and resistant cells (D54-R and U87-R) is enhanced significantly under hyperoxia. Both Methazolastone and hyperoxia are associated with increased phosphorylation of ERK p44/42 MAPK (Erk1/2), but to a lesser extent in D54-R cells, suggesting that Erk1/2 activity may be involved in regulation of hyperoxia and Methazolastone-mediated cell death. Hyperoxia enhances Methazolastone toxicity in GBM cells by induction of apoptosis, possibly via MAPK-related pathways. ^[2] Methazolastone induces in monocytes the DNA damage response pathways ATM-Chk2 and ATR-Chk1 resulting in p53 activation. ^[3] Chronic Methazolastone exposure results in acquired Methazolastone-resistance and elevates miR-21 expression. ^[4] Methazolastone treatment triggers endoplasmic reticula (ER) stress with increased expression of GADD153 and GRP78 proteins, and deceases pro-caspase 12 protein. Methazolastone induces autophagy through mitochondrial damage- and ER stress-dependent mechanisms to protect glioma cells. ^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Kelly	NUL6UXc1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3fONFQ5KGh?		Mk\XTWM2OD1zM{muNlDjiIoEsfMAjVUvQTVizszN	Ml63QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NkCyPFIoRjJ3OU[wNlgzRC:jPh?=
KellyCis83	NG\LcJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYntd\|RZPDhiaB?=		NVLtWZQzUUN3ME2yOVEvODEkgJpCtgKBkTF3Lke1JO69VQ>?	NGHI[pQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm2NFI5Oid-MkW5OlAzQDJ:L3G+
SK-N-AS	MnLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYPrS4pbPDhiaB?=		M2Xu[WlEPTB;MkK3Mlcx6oDLwsJihKkzOi5zNTFOwG0>	M2nvNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OU[wNlgzLz5{NUm2NFI5OjxxYU6=
SK-N-ASCis24	NULBSZk{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MY[0PEBp		MYHJR\|UxRTR6MD62NQKBkcLz4pEJNVAyNjF3IN88US=>	NXXS[4xNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OlAzQDJpPkK1PVYxOjh{PD;hQi=>
CHP-212	M4rTWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NX76XnRWPDhiaB?=		M3i0TGlEPTB;Nz65O-KBkcLz4pEJNE43QSEQvF2=	MoGyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NkCyPFIoRjJ3OU[wNlgzRC:jPh?=
CHP-212Cis100	NHe4TWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUK3eIh4PDhiaB?=		MVvJR\|UxRTlwNUZihKnDueLCiUCuPFgh\|ryP	Mki1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NkCyPFIoRjJ3OU[wNlgzRC:jPh?=
U87	NFHtbZZHfW6ldHnvckBCe3OjeR?=	NYH0Z2hzOTByIN88US=>	MlvmNlQuPzJiaB?=		NV7yOpNKcW6mdXPld{BF[1JzIHX4dJJme3Orb36=	MojjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MEi4OlgoRjJ3OEC4PFY5RC:jPh?=
LN229	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUewMVUxKM7:TR?=			M{f5c2lEPTB;MU[g{txO	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd3MEK3N{c,OjV5NUCyO\|M9N2F-
TR-LN229	M3zKZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUKwMVUxKM7:TR?=			M3zrZWlEPTB;N{eg{txO	M1XNXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{WwNlc{Lz5{NUe1NFI4OzxxYU6=
U87	NVTNZWN5SXCxcITvd4l{KEG\|c3H5	M3[5V\|DjiJN{MEFihKnDvU1?	MXiyOEBp		NGTaXXFmdmijbnPld{BEWSCrbnT1Z4VlKGGyb4D0c5Nqew>?	M4PrclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkixOlY5Lz5{NU[4NVY3QDxxYU6=
U251MG	MUDBdI9xfG:\|aYOgRZN{[Xl?	MV:xNFDDqM7:TR?=	NYPKd21GPDhiaB?=	MWrQRnM>	MmrabY5lfWOnczDhdI9xfG:\|aYO=	NULoOnkyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2PFA1PjRpPkK1OlgxPDZ2PD;hQi=>
U87MG	M{GwPWFxd3C2b4Ppd{BCe3OjeR?=	MYSxNFDDqM7:TR?=	MnfkOFghcA>?	MUXQRnM>	NVv2NoQ{cW6mdXPld{BieG:ydH;zbZM>	M{XnSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkiwOFY1Lz5{NU[4NFQ3PDxxYU6=
U87	NHXIRYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXznN\|FxPTBvM{WwJO69VQ>?	M17aSVQ5yqCqwrC=		MWTpcohq[mm2czDj[YxtKGe{b4f0bEB{dGmpaITsfS=>	M{joWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUW0NlI{Lz5{NUW1OFIzOzxxYU6=
U118	MmX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3P5cFUxNTN3MDFOwG0>	NIHQWIE1QMLiaNMg		NIDnenFqdmirYnn0d{Bk\WyuIHfyc5d1cCC\|bHnnbJRtgQ>?	Ml7oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NUSyNlMoRjJ3NUW0NlI{RC:jPh?=
U87	NUnhWGNkTnWwY4Tpc44hSXO\|YYm=	NFPzVVYzPTBxM{WwJO69VQ>?	MUm0POKhcMLi		Mn;F[Y5p[W6lZYOgWG1ZNWmwZIXj[YQheC2SS1OtdIFvKGSnY4LlZZNm	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV3NEKyN{c,OjV3NUSyNlM9N2F-
U118	MmL0SpVv[3Srb36gRZN{[Xl?	MWiyOVAwOzVyIN88US=>	M1TWWlQ5yqCqwrC=		NWX3fmFK\W6qYX7j[ZMhXE2[LXnu[JVk\WRicD3QT2MueGGwIHTlZ5Jm[XOn	NUjkO3lSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OVQzOjNpPkK1OVU1OjJ\|PD;hQi=>
U87	NUDteWtuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PGNFI2OC9\|NUCg{txO	Mki3OFjDqGkEoB?=		NHrrXoVqdmO{ZXHz[ZMhfGinIIDldoNmdnSjZ3Wgc4Yh[2WubIOgbY4hWyCjbnSgS\|IwVcLiY3;0doVifGWmIIfpeIghXE2[	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV3NEKyN{c,OjV3NUSyNlM9N2F-
A375	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NEDyVWw1QMLiaNMg		MnvYTWM2OD1{NkWg{txO	Ml7YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3MkS1OVIoRjJ3NUK0OVUzRC:jPh?=
A2058	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3;PRlQ5yqCqwrC=		MX;JR\|UxRTF{IN88US=>	M4TveFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUK0OVUzLz5{NUWyOFU2OjxxYU6=
M238	M2Tad2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MljFOFjDqGkEoB?=		M1PoWmlEPTB;NECg{txO	Mmf1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3MkS1OVIoRjJ3NUK0OVUzRC:jPh?=
M249	M{TPdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M36zTFQ5yqCqwrC=		M13He2lEPTB;MkW0JO69VQ>?	M3\GSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUK0OVUzLz5{NUWyOFU2OjxxYU6=
M21	M2\B[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUO0POKhcMLi		Mm\OTWM2OD1{MkGg{txO	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV{NEW1Nkc,OjV3MkS1OVI9N2F-
U251	Ml3HR5l1d3SxeHn0fUBCe3OjeR?=	MoD1NlAh\|ryPwrC=	MljuOFjDqGkEoB?=		MYTy[YR2[2WmczD0bIUheGW{Y3XueIFo\XNib3[gZ49td26rZYOg[o9zdWWm	NFfPNW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSzOFM5OSd-MkW0N\|Q{QDF:L3G+
LN229	MUTDfZRwfG:6aYT5JGF{e2G7	NEDSbmQzOCEQvF5CpC=>	NWHyOZYxPDkEoHlCpC=>		MU\y[YR2[2WmczD0bIUheGW{Y3XueIFo\XNib3[gZ49td26rZYOg[o9zdWWm	NX;wNotbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0N\|Q{QDFpPkK1OFM1OzhzPD;hQi=>
U373MG-LUC	MmPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M17IXlczKGh?		NX;mPJVnUUN3ME62NFAh\|ryP	MnO1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2M{G5OVMoRjJ3NEOxPVU{RC:jPh?=
U87	NVvIdYpbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTTSXFuOjVvMkCwJO69VQ>?	M3uwblQ5yqCqwrC=		NITOUItqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRyMEe0OUc,OjV2MEC3OFU9N2F-
U251	NX;FPJBwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUCyOU0zODBizszN	MWe0POKhcMLi		NXjOZ3p7cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MkG2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MEC3OFUoRjJ3NECwO\|Q2RC:jPh?=
U251	NVTjblRZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPwVJUyODBvNECwJO69VQ>?	NHXGOWw4Oi97NjDo		MXT0bIUh[W62aT3wdo9tcW[ncnH0bZZmKGWoZnXjeEBk[W5iYnWg[Y5p[W6lZXSgZpkh\2:\|c4nwc4wh\W6qYX7j[YQhyqB?	MlzhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|N{WyO\|EoRjJ3M{e1NlcyRC:jPh?=
U373	NEP0OXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2nWZ\|ExOC12MECg{txO	M1XseFczNzl4IHi=		NXzkSGZ[fGinIHHueIkueHKxbHnm[ZJifGm4ZTDl[oZm[3RiY3HuJIJmKGWwaHHuZ4VlKGK7IHfvd5N6eG:uIHXubIFv[2WmINMg	M13JNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{e1NlcyLz5{NUO3OVI4OTxxYU6=
U343	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3e4ZVExOC12MECg{txO	Ml7FO\|IwQTZiaB?=		NFjSfIR1cGViYX70bU1xem:uaX\ldoF1cX[nIHXm[oVkfCClYX6gZoUh\W6qYX7j[YQh[nliZ3;zd5lxd2xiZX7oZY5k\WRiwrC=	M{PrNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{e1NlcyLz5{NUO3OVI4OTxxYU6=
U87MG-luc2	M3SyeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHVNVAxNTRyMDFOwG0>	MVi3Nk86PiCq		MUf0bIUh[W62aT3wdo9tcW[ncnH0bZZmKGWoZnXjeEBk[W5iYnWg[Y5p[W6lZXSgZpkh\2:\|c4nwc4wh\W6qYX7j[YQhyqB?	NF7aZnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO3OVI4OSd-MkWzO\|UzPzF:L3G+
U87	MWPGeY5kfGmxbjDBd5NigQ>?	NGf4dFYzODBizszN	NFjwToQ1QCCq		Mn:wbY5kemWjc3XzJGJTS0N\|IH3SUmEh\XiycnXzd4lwdg>?	M1XIbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{O3O\|IyLz5{NUOzO\|czOTxxYU6=
U251	MlTJSpVv[3Srb36gRZN{[Xl?	NGnnW2kzODBizszN	NUTnUZlTPDhiaB?=		M2ixc4lv[3KnYYPld{BDWkOFMzDtVm5CKGW6cILld5Nqd25?	NIjLPYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOzO\|czOSd-MkWzN\|c4OjF:L3G+
A172	MkTkSpVv[3Srb36gRZN{[Xl?	MWiyNFAh\|ryP	M37kelQ5KGh?		MYrpcoNz\WG\|ZYOgRnJESzNibWLORUBmgHC{ZYPzbY9v	NU\GcHh[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzN\|c4OjFpPkK1N\|M4PzJzPD;hQi=>
U251	MV7GeY5kfGmxbjDBd5NigQ>?	MXOyNFAh\|ryP	M4fLTVQ5KGh?		M1f2OIlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBDWkODMTygRnJESTJuIGLBSFUyKGGwZDDGRW5ETDJ?	MnvpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|M{e3NlEoRjJ3M{O3O\|IyRC:jPh?=
A172	NXvsTmZiTnWwY4Tpc44hSXO\|YYm=	MYGyNFAh\|ryP	NV\qZoR1PDhiaB?=		MkXIbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGJTS0FzLDDCVmNCOixiUlHEOVEh[W6mIF\BUmNFOg>?	Mm\GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|M{e3NlEoRjJ3M{O3O\|IyRC:jPh?=
U87	NVnIO\|JoTnWwY4Tpc44hSXO\|YYm=	MXKyNFAh\|ryP	MoKzNlQwPzJxMUKwJIg>		MnLHbY5kemWjc3XzJO6{UDKDWDDmc4NqKG[xcn3heIlwdiC2aX3lMYRmeGWwZHXueIx6	NH33UHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOzO\|czOSd-MkWzN\|c4OjF:L3G+
U251	NIHPZnZHfW6ldHnvckBCe3OjeR?=	MmDsNlAxKM7:TR?=	MnXKNlQwPzJxMUKwJIg>		NVP0O\|BzcW6lcnXhd4V{KM7\|SELBXEBnd2OrIH\vdo1ifGmxbjD0bY1mNWSncHXu[IVvfGy7	NXjGT\|hqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzN\|c4OjFpPkK1N\|M4PzJzPD;hQi=>
A172	M4XieGZ2dmO2aX;uJGF{e2G7	NGG5UmszODBizszN	NVPqcIE4OjRxN{KvNVIxKGh?		NHnQXHVqdmO{ZXHz[ZMh\|rOKMlHYJIZw[2liZn;ycYF1cW:wIITpcYUu\GWyZX7k[Y51dHl?	M1f5PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{O3O\|IyLz5{NUOzO\|czOTxxYU6=
SNB19V	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmfSO{Bl	NInweWFFVVOR	NWXCVohrT0l3ME2zOU44yrFzMjFOwG0>	NUXjfoY6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|c1PDFpPkK1Nlc4PDRzPD;hQi=>
SNB19M	NVPwWXl4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEG2cYg4KGR?	NYPieoxZTE2VTx?=	MVLHTVUxRTR4OT65xtE5QCEQvF2=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{S0NUc,OjV{N{e0OFE9N2F-
SNB19VR	M2O0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NX6ySnFRPyCm	NX\tSI1kTE2VTx?=	NW\XbGtJT0l3ME2yPFAvOsLzMUig{txO	M{DMW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFQyLz5{NUK3O\|Q1OTxxYU6=
U373V	MlLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHTOU\|k4KGR?	MkH1SG1UVw>?	NIjSS4tIUTVyPU[4MlDDuTN{IN88US=>	M3HHPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFQyLz5{NUK3O\|Q1OTxxYU6=
U373M	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4fKTlch\A>?	M2DFOmROW09?	NXO3bXFHT0l3ME2zOlgvP8LzOE[g{txO	NF;Pb\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3O\|Q1OSd-MkWyO\|c1PDF:L3G+
U373VR	NUXxNXhYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYTL[YFLPyCm	MWLEUXNQ	NFjaOoJIUTVyPUK4PE45yrF\|MzFOwG0>	M1n1bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFQyLz5{NUK3O\|Q1OTxxYU6=
U87MG	M3;TZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MoTrO{Bl	MW\EUXNQ	MYHHTVUxRTN6LkRCtVIxKM7:TR?=	NFXpWHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3O\|Q1OSd-MkWyO\|c1PDF:L3G+
HCT116	NXH5TGZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4e1R\|ch\A>?	NFjOd2VFVVOR	NHftWIJIUTVyPUW3PU46yrF\|MjFOwG0>	NIfDUIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3O\|Q1OSd-MkWyO\|c1PDF:L3G+
DLD1	MkjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlXKO{Bl	M4e3Z2ROW09?	NUDsUJl6T0l3ME21NFEvPMLzOUOg{txO	NXHHbZJlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|c1PDFpPkK1Nlc4PDRzPD;hQi=>
MRC5	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MkTOO{Bl	NUHZNpNoTE2VTx?=	MYjHTVUxRTR2OT60xtE5KM7:TR?=	NX3xSolZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|c1PDFpPkK1Nlc4PDRzPD;hQi=>
SNB19V	M{j0TGZ2dmO2aX;uJGF{e2G7	NGrLflgyODBizszNxsBVVVp?	MVqwMVczKGh?		MkfTbY5kemWjc3XzJO6{UDKDWDDlfJBz\XO\|aX;uJIJmfHenZX6gNVYh[W6mIEeyJIg>	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{S0NUc,OjV{N{e0OFE9N2F-
T98G	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV:1M\|ExNzF3IN88US=>	MX:yOOKhcA>?		M2f2Rolv\HWlZYOgZ4VtdCCmZXH0bEBld3OnLXTldIVv\GWwdHz5JIFnfGW{IHPvcoNwdWm2YX70MZRmdW:8b3zvcYll\SC5aYToJG5R\TZvUFTU	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4Mkm2NUc,OjV{NkK5OlE9N2F-
U251	NHi4cmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVy1M\|ExNzF3IN88US=>	M1Ttd\|I1yqCq		MUjpcoR2[2W\|IHPlcIwh\GWjdHig[I9{\S2mZYDlcoRmdnSueTDh[pRmeiClb37jc41qfGGwdD30[Y1wgm:ub33p[IUhf2m2aDDOVIU3NVCGVB?=	NXPpfFRNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlI6PjFpPkK1NlYzQTZzPD;hQi=>
T98G	NHKxTm9HfW6ldHnvckBCe3OjeR?=	MorRNVUh\|ryP	NEXoSmkzPMLiaB?=		MkDqbY5kemWjc3XzJGRPSS2ocnHncYVvfGG2aX;uJIlvKE6SZU[tVGRVKHS{ZXH0[YQh\2yrb33hJINmdGy\|	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4Mkm2NUc,OjV{NkK5OlE9N2F-
U251	MXzGeY5kfGmxbjDBd5NigQ>?	MmnMNVUh\|ryP	M4TnOVI1yqCq		MnjBbY5kemWjc3XzJGRPSS2ocnHncYVvfGG2aX;uJIlvKE6SZU[tVGRVKHS{ZXH0[YQh\2yrb33hJINmdGy\|	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4Mkm2NUc,OjV{NkK5OlE9N2F-
U-87 MG	NFvDW3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFvReoc4OiCq		M{H0dWlEPTB;MD65N{BuVcLi	MnPGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NEWzN\|IoRjJ3MkS1N\|MzRC:jPh?=
U-118 MG	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3LIOFczKGh?		MojtTWM2OD1zLkC1JI1OyqB?	M4[2c\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkS1N\|MzLz5{NUK0OVM{OjxxYU6=
U87	M1WwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXKyOEBp		MoL3TWM2OD1{NkCuN\|Qh\|ryPwrC=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF5M{KzN{c,OjVzN{OyN\|M9N2F-
U87 GSLCs	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MX[yOEBp		NY\yZYE1UUN3ME23OlYvOTFizszNxsA>	NXH2[VlvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxO\|MzOzNpPkK1NVc{OjN\|PD;hQi=>
U87MG	NUjzfIFyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlzwO\|IhcA>?		NVPJSHNIUUN3ME2xOU43OjVizszNxsA>	NVPSUoVyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOVA6OTVpPkK1NFUxQTF3PD;hQi=>
U251	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnoNVAxNTRyMDFOwG0>	NGXlOFM1QCCq	MYLEUXNQ	Ml3PbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NF7VWnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[yN\|c{Pid-MkS2NlM4OzZ:L3G+
U87	MmTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\lNVAxNTRyMDFOwG0>	MofBOFghcA>?	M4[1OWROW09?	MVTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MnvZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MkO3N\|YoRjJ2NkKzO\|M3RC:jPh?=
MDA-MB-231-br	M3T0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW\sbIt7OC1zMDFOwG0>	M2C0SVQ5KGh?	M3Szd2ROW09?	NWDldHlIcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ{M{ezOkc,OjR4MkO3N\|Y9N2F-
HCC-1937	NH;UdIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzoSlQxNTNyMDFOwG0>	NGLleIk1QCCq	NWjN[2o6TE2VTx?=	MnjPbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	M4m5e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkKzO\|M3Lz5{NE[yN\|c{PjxxYU6=
MDA-MB-231	MoTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXmwMVQxKM7:TR?=	Ml;0OFghcA>?	MXXEUXNQ	M1zlWolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	M1Xv[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkKzO\|M3Lz5{NE[yN\|c{PjxxYU6=
MDA-MB-468	MlzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDwSXYxNTVyMDFOwG0>	NVfPfINkPDhiaB?=	MkDDSG1UVw>?	NXLhflE2cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NWLERXdSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NlM4OzZpPkK0OlI{PzN4PD;hQi=>
T47D	NXX6SmZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVOwMVExOCEQvF2=	NFznepg1QCCq	M2HrbmROW09?	M4HaT4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	M1fPSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkKzO\|M3Lz5{NE[yN\|c{PjxxYU6=
MCF7	M4XJWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LhOVAuOTByMDFOwG0>	M1W3fFQ5KGh?	MXfEUXNQ	NIjQfHNqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ{M{ezOkc,OjR4MkO3N\|Y9N2F-
Hs683	NW\MUXhlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml\ZNE0yODByIN88US=>	M{Xmdlk3KGh?		M1viPWlEPTB;MUK4Mlkh\|ryP	NF\ucpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES5OVkxPyd-MkS0PVU6ODd:L3G+
U87	NYDLR5FZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1G4eFAuOTByMDFOwG0>	MkTDPVYhcA>?		M{PwbWlEPTB;MUiuOFUh\|ryP	NIjMUYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES5OVkxPyd-MkS0PVU6ODd:L3G+
LNZ308	NEf3XFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTleZg3OC1zMECwJO69VQ>?	MUi5OkBp		M3\EOGlEPTB;M{K2Mlch\|ryP	Mmr0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2OUW5NFcoRjJ2NEm1PVA4RC:jPh?=
U87	MXLBdI9xfG:\|aYOgRZN{[Xl?	MVmxNFAh\|ryP	MnLpOFghcA>?	NWOzSnF5TE2VTx?=	M3jsXIlv[3KnYYPld{B1cGViY3HzdIF{\S1\|L{egZYN1cX[rdIm=	M4\pdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEixOVg3Lz5{NES4NVU5PjxxYU6=
U251	Ml3mRZBweHSxc3nzJGF{e2G7	MYexNFAh\|ryP	NXHCWGJsPDhiaB?=	MVjEUXNQ	MU\pcoNz\WG\|ZYOgeIhmKGOjc4Dhd4UuOy95IHHjeIl3cXS7	NF;0VmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES4NVU5Pid-MkS0PFE2QDZ:L3G+
U251	MlzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYmyOEBp		MX;JR\|UxRTh4LkK55qCKyrIkgJmxMlU5KM7:TR?=	NWS1eGxORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzNlY6PTRpPkK0N\|I3QTV2PD;hQi=>
U251	NXK5OVhbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Ml3EOFghcA>?		NITVOZFKSzVyPUe1MlM16oDLwsJihKkyNjB{IN88US=>	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN{Nkm1OEc,OjR\|Mk[5OVQ9N2F-
U251	MnrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NF\DXJE4OiCq		NUKyfVVGUUN3ME23Nk41OuLCidMx5qCKOS52NTFOwG0>	MmDJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|Mk[5OVQoRjJ2M{K2PVU1RC:jPh?=
U251	NU\tbFRFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXjMNpBxQTZiaB?=		NX;iNHhTUUN3ME22PU45OuLCidMx5qCKOy5yNDFOwG0>	MoT2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|Mk[5OVQoRjJ2M{K2PVU1RC:jPh?=
T98G	NX:5V5FpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3MNE04PTBizszN	M1LaUlczNzl4IHi=		Mm\abY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NGniOGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEOyOFA5OCd-MkSzNlQxQDB:L3G+
U251-MG	MkT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWTjfVZ7OC16MECg{txO	M4PmbVczKGh?		M{L2dIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	Ml\ZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOUO2N\|AoRjJ2MEmzOlMxRC:jPh?=
D54-MG	M4rX[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW\MbVQyOC16MECg{txO	M3i5OFczKGh?		M4H2Z4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	MnLPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOUO2N\|AoRjJ2MEmzOlMxRC:jPh?=
SHG-44	NEnCSlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MonqNVAuOjByIN88US=>	NFjMXJY6PiCq		M3T5Z2lEPTB;OT63N{DDuSB{LkGyJO69VQ>?	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB4NUW2PUc,OjRyNkW1Olk9N2F-
U373	NFnKblNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYr2OYlFOTBvMkCwJO69VQ>?	NY\2fGpFQTZiaB?=		Ml3rTWM2OD1zMD6xN{DDuSBzLkCyJO69VQ>?	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB4NUW2PUc,OjRyNkW1Olk9N2F-
HT-29	NYL3OodDTnWwY4Tpc44hSXO\|YYm=	NX\w[nB2PTByIN88US=>	M3LwdVI1NzR6IHi=		Mn3N[Y5p[W6lZYOgeIhmKGyndnXsd{Bw\iEQsz3INmFZyqB?	NXT1Omx2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwN\|gxPjhpPkK0NFM5ODZ6PD;hQi=>
PC-3	M4nxemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2nCOFAuOjVizszN	MXS0PEBp		MV3pcohq[mm2czDj[YxtKGe{b4f0bEB4cGmlaDDjZY4h[mVicH;0[Y51cWG2ZXSgZpkhdHmlb4DlcoU>	Mm\6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5NE[5N\|QoRjJ\|N{S2PVM1RC:jPh?=
PC-3	NGDERlNCeG:ydH;zbZMhSXO\|YYm=	MYCyOUDPxE1?	M4LQd\|Q5KGh?		MkLEbY5lfWOnczDhdI9xfG:\|aYOge4hq[2hiY3HuJIJmKHCxdHXueIlifGWmIHL5JIx6[2:yZX7l	NGrqS209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e0Olk{PCd-MkO3OFY6OzR:L3G+
T98G	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnfaOVAuPDByIN88US=>	NWjG[2ViOTR2IHi=		M1TKSolvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzdzNUS5PUc,OjN5MUW0PVk9N2F-
U87-MG	M1\YeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2P1NFExOCEEtV2=	NWPveVJKPzJiaB?=		NUfKWoFIcW6qaXLpeJMh[2WubDDndo94fGhid3jpZ4gh[2GwIHLlJIVvcGGwY3XkJIJ6KEeWQh?=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ7Nke4PEc,OjN4OU[3PFg9N2F-
U251-MG	Mo\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWLWOVAxOTByINM1US=>	NXvFRpkyPzJiaB?=		NFrKO4dqdmirYnn0d{Bk\WyuIHfyc5d1cCC5aHnjbEBk[W5iYnWg[Y5p[W6lZXSgZpkhT1SE	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ7Nke4PEc,OjN4OU[3PFg9N2F-
LNT-229	NYTDUHFbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVzISGFlOy1zMECg{txO	MWmyOEBp		MoXtbY5pcWKrdIOgZ4xwdm:pZX7pZ{B{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NW\mfIVHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2Olc3OzJpPkKzOlY4PjN{PD;hQi=>
T98G	NH70XHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4DJ[FExNTdyMDFOwG0>	M{jMUFI1KGh?		M3\CN4lvcGmkaYTzJINtd26xZ3XubYMhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	Mm\aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4Nke2N\|IoRjJ\|Nk[3OlMzRC:jPh?=
U87	NF\O[JFHfW6ldHnvckBCe3OjeR?=	M3jZeVExOCEEtV2=	Ml\HN{Bp		NI[3WI9mdGW4YYTld{B1cGVibHX2[Yx{KG:oIIDDbIsyKGGwZDDwR4hsOg>?	M{\uN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|Nk[3OFY6Lz5{M{[2O\|Q3QTxxYU6=
HCT116	NUDHOZJyTnWwY4Tpc44hSXO\|YYm=	MYCxNFAhyrWP	Mn60N{Bp		NWjocVBycW6mdXPld{B1cGViQ3jrNUBRcG:\|cHjvdplt[XSrb36=	NEfPVIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[2O\|Q3QSd-MkO2Olc1Pjl:L3G+
HCT3-6	NIm4VFFHfW6ldHnvckBCe3OjeR?=	MUixNFAhyrWP	MUGzJIg>		NHLHb4VqdmS3Y3XzJJRp\SCFaHuxJHBpd3OyaH;yfYxifGmxbh?=	NX;RcGI6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2Olc1PjlpPkKzOlY4PDZ7PD;hQi=>
U-87	NGLxRlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXmco0xNTRyIN88US=>	NHrjUlEyOiCm		M4T6PIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ2NUeyPUc,OjN4NEW3Nlk9N2F-
U-87	NIG4VmZCeG:ydH;zbZMhSXO\|YYm=	MWmwMVQxKM7:TR?=	NH7VdI8{NzZiZB?=		M1znd4lv\HWlZYOgZZBweHSxc3nzJIlvKGKxdHig[I9{\S1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>?	M1rCOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkS1O\|I6Lz5{M{[0OVczQTxxYU6=
U-87	MnLZSpVv[3Srb36gRZN{[Xl?	NHXtdVIxNTRyIN88US=>	MUCzM\|Yh\A>?		NXTyVW02cW6mdXPld{BifXSxcHjh[5khcW5iYn;0bEBld3OnLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ2NUeyPUc,OjN4NEW3Nlk9N2F-
GB-SCC010	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4TQ[lQh\A>?		NXL0ZVF3UUN3ME2yNlYh\|ryP	NHTKbo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xNlc2PSd-MkO2NVI4PTV:L3G+
GB-SCC026	M4LFZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXu0JIQ>		NFnubIdKSzVyPUWzMlEh\|ryP	NVvI[ItFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVI4PTVpPkKzOlEzPzV3PD;hQi=>
GB-SCC028	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmWxOEBl		MmfjTWM2OD1zNkeg{txO	MnfTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUK3OVUoRjJ\|NkGyO\|U2RC:jPh?=
U87	NV70T4dYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYm3dWh4PCCm		Ml6xTWM2OD12NT6yJO69VQ>?	NG[1c2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xNlc2PSd-MkO2NVI4PTV:L3G+
U87 stem cell	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGP1SZI1KGR?		NWrmXGppUUN3ME22Ok44KM7:TR?=	NEj2VGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xNlc2PSd-MkO2NVI4PTV:L3G+
TLX5 lymphoma	MXTDfZRwfG:6aXPpeJkh[XO\|YYm=				NIDTeG9KSzVyIE2gOUDPxE1?	NX7aVmhyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxN{ezPVAxQCd-N{ezPVAxQDxxYU6=
GM892 A	M{[wTWN6fG:2b4jpZ4l1gSCjc4PhfS=>				NInrb5BKSzVyIE2gO{43KM7:TR?=	NUPQXlhVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxN{ezPVAxQCd-N{ezPVAxQDxxYU6=
TLX5 lymphoma	NVjsdFV4S3m2b4TvfIlkcXS7IHHzd4F6				M3TzNGlEPTBiPTC1JO69VQ>?	M2rj[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{NEW5NFE1Lz5zMkS1PVAyPDxxYU6=
HCT116	NIDxN29EgXSxdH;4bYNqfHliYYPzZZk>		MnHlOEBl[Xm\|		M2WyOWlEPTBiPTC0MlM1KM7:TR?=	M1n2[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OECwPFA{Lz5zOUiwNFgxOzxxYU6=
SNB75	M4ixeGFvfGmycn;sbYZmemG2aY\lJIF{e2G7	NFmzN\|cyOCC3TR?=	M4jnSlI1KGi{cx?=		M2PyO2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU17CO\|Uh[2WubIOgZZQhOTBidV2gZYZ1\XJiMkSgbJJ{KGK7IGPSRkBie3OjeR?=	M1SwUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Mk[4OVI3Lz5{MkK2PFUzPjxxYU6=
C6	M1yyZmFvfGmycn;sbYZmemG2aY\lJIF{e2G7	NFPNTokyODBidV2=	M3fIflQ5KGi{cx?=		MojCRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDyZZQhSzZiY3XscJMh[XRiMUCwJJVOKGGodHXyJFQ5KGi{czDifUBv\XW2cnHsJJJm\CCrbnPvdpBwemG2aX;uJIF{e2G7	NHjnNGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK2PFUzPid-MkKyOlg2OjZ:L3G+
SF295	MkHSRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?	MYOxNEB2VQ>?	MX[yOEBpenN?		MlTGRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVRkK5OUBk\WyuczDheEAyOCC3TTDh[pRmeiB{NDDodpMh[nliU2LCJIF{e2G7	M4\XelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Mk[4OVI3Lz5{MkK2PFUzPjxxYU6=
U87	MUjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NEfpepI2KGSjeYO=		NE\kXWhKSzVyIE2gOFkh\|ryP	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjZyOEO4PUc,OjJ4MEizPFk9N2F-
U138MG	MnGyR5l1d3SxeHnjbZR6KGG\|c3H5		MXO0PEBpenN?		NHG3NpZKSzVyIE2gNlYh\|ryP	NEfxemg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C2PVY5Oid-MkOwOlk3QDJ:L3G+
C6	MVHDfZRwfG:6aXPpeJkh[XO\|YYm=		Ml7IOFghcHK\|		NWi4XZF7UUN3MDC9JFM1KM7:TR?=	NELPW\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C2PVY5Oid-MkOwOlk3QDJ:L3G+
A2780	M3;OV2FvfGm2dX3vdkBie3OjeR?=		NU\BUJhyPSCmYYnz		NHPCN4dKSzVyIE2gPE42KM7:TR?=	MojhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6OUW2NlAoRjJ\|OEm1OlIxRC:jPh?=
A2058	MoXVRY51cXS3bX;yJIF{e2G7		MWC1JIRigXN?		NVntNpNNUUN3MDC9JFM2NjVizszN	Ml\aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6OUW2NlAoRjJ\|OEm1OlIxRC:jPh?=
SNB19	Mn7GRY51cXS3bX;yJIF{e2G7		NY\BTmhJPSCmYYnz		MkHZTWM2OCB;IEO3JO69VQ>?	NIXYT\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i5OVYzOCd-MkO4PVU3OjB:L3G+
M8	NYfDZ2dCSXCxcITvd4l{KGG\|c3H5	M2[0dFUxKHSxIEGwNEB2VQ>?	M13wSFQ5KGi{cx?=		NFjtOXdKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIF24JINmdGy\|IHHzd4V{e2WmIHHzJIFxd3C2b4TpZ{9v\WO{b4TpZ{Bk\WyuczDheEA2OCC2bzCxNFAhfU1iYX\0[ZIhPDhiaILzJIJ6KEGSQz3sZYJmdGWmIHHucoV5cW5iVjDhcoQhPy2DQVSgd5RicW6rbnetZoF{\WRiZnzve{BkgXSxbXX0dolkKGGwYXz5d4l{	Mnq1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzMkW4O\|coRjJ2MUK1PFc4RC:jPh?=
SK-MEL-30	NUPNPYE3SXCxcITvd4l{KGG\|c3H5	NWDQWZByOTByIIXN	MnrJOFghcHK\|		MlKzTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCVSz3NSWwuOzBiY3XscJMh[XO\|ZYPz[YQh[XNiYYDvdJRwfGmlL37lZ5JwfGmlIHPlcIx{KGG2IEGwNEB2VSCjZoTldkA1QCCqcoOgZpkhSVCFLXzhZoVt\WRiYX7u[ZhqdiCYIHHu[EA4NUGDRDDzeIFqdmmwZz3iZZNm\CCobH;3JIN6fG:vZYTybYMh[W6jbInzbZMhemWuYYTpeoUhfG9iY3;ueJJwdA>?	NGDYbHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGyOVg4Pyd-MkSxNlU5Pzd:L3G+
SK-MEL-30	M1nmXGFxd3C2b4Ppd{Bie3OjeR?=	NVPGTo97PTBidV2=	MkWyOFghcHK\|		NVH6fFUxUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDTT{1OTUxvM{CgZ4VtdHNiYYPz[ZN{\WRiYYOgZZBweHSxdHnjM45m[3KxdHnjJINmdGy\|IHH0JFUxKHWPIHHmeIVzKDR6IHjyd{BjgSCDUFOtcIFj\WynZDDhco5mgGmwIG[gZY5lKDdvQVHEJJN1[WmwaX7nMYJie2WmIH\sc5ch[3m2b33leJJq[yCjbnHsfZNqeyC{ZXzheIl3\SC2bzDjc451em:u	NGfEVpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGyOVg4Pyd-MkSxNlU5Pzd:L3G+
MNT1	Mo\QRZBweHSxc3nzJIF{e2G7	M1XycFExOCC3TR?=	NY\xfJduPDhiaILz		MoLETY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCPTmSxJINmdGy\|IHHzd4V{e2WmIHHzJIFxd3C2b4TpZ{9v\WO{b4TpZ{Bk\WyuczDheEAyODBidV2gZYZ1\XJiNEigbJJ{KGK7IFHQR{1t[WKnbHXkJIFvdmW6aX6gWkBidmRiNz3BRWQhe3SjaX7pcocu[mG\|ZXSg[oxwfyCleYTvcYV1emmlIHHuZYx6e2m\|IILlcIF1cX[nIITvJINwdnS{b3y=	NH23cG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGyOVg4Pyd-MkSxNlU5Pzd:L3G+
MNT1	MX3BdI9xfG:\|aYOgZZN{[Xl?	M{H0TVUxKHWP	MX20PEBpenN?		M2nxU2lv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iTV7UNUBk\WyuczDhd5Nme3OnZDDhd{BieG:ydH;0bYMwdmWlcn;0bYMh[2WubIOgZZQhPTBidV2gZYZ1\XJiNEigbJJ{KGK7IFHQR{1t[WKnbHXkJIFvdmW6aX6gWkBidmRiNz3BRWQhe3SjaX7pcocu[mG\|ZXSg[oxwfyCleYTvcYV1emmlIHHuZYx6e2m\|IILlcIF1cX[nIITvJINwdnS{b3y=	NH3RXnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGyOVg4Pyd-MkSxNlU5Pzd:L3G+
A2780	NWLIdnhNS3m2b4TvfIlkcXS7IHHzd4F6		M{nPSFUh\GG7cx?=		MVnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBNlc5OCClZXzsd{Bi\nSncjC1JIRigXNiYomgUXRVKGG\|c3H5	MoPjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC0NVgoRjJ2OUCwOFE5RC:jPh?=
A2780/CP70	MnTTR5l1d3SxeHnjbZR6KGG\|c3H5		NVG2XG9JPSCmYYnz		MkD5R5l1d3SxeHnjbZR6KGGpYXnud5QhVU2ULXTl[olkcWWwdDDoeY1idiCDMke4NE9EWDdyIHPlcIx{KGGodHXyJFUh\GG7czDifUBOXFRiYYPzZZk>	NYHlSYlGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA1OThpPkK0PVAxPDF6PD;hQi=>
GBM 047T	NIroRWhCdnSrdIXtc5Ih[XO\|YYm=	MYGyNEB2VQ>?	NU[0fWVHOSC2bzCyJJdm\Wu\|		NHPVVoJVfW2xcnnjbYRidCCnZn\lZ5QhcW5icHH0bYVvfCCmZYLpeoVlKEeETTCwOFdVKGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDu[ZVzd3OyaHXy[UBnd3KvYYTpc44h[XRiMkCgeW0h[W[2ZYKgNUB1dyB{IIfl[Yt{KGK7IEPEJJR2dW:{IHPsc45w\2WwaXOgZZN{[Xl?	MoHWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|NUW1N\|IoRjJ4M{W1OVMzRC:jPh?=
GBM 464T	NIH2RnBCdnSrdIXtc5Ih[XO\|YYm=	NEiyU5UzOCC3TR?=	NVXn[m9tOSC2bzCyJJdm\Wu\|		NF;MXVRVfW2xcnnjbYRidCCnZn\lZ5QhcW5icHH0bYVvfCCmZYLpeoVlKEeETTC0OlRVKGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDu[ZVzd3OyaHXy[UBnd3KvYYTpc44h[XRiMkCgeW0h[W[2ZYKgNUB1dyB{IIfl[Yt{KGK7IEPEJJR2dW:{IHPsc45w\2WwaXOgZZN{[Xl?	NXjacI1uRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zOVU2OzJpPkK2N\|U2PTN{PD;hQi=>
U87MG	M3H0bWZ2dmO2aX;uJIF{e2G7		MYKzJIhzew>?		M4DJdmlv\HWldHnvckBw\iCGTlGgZYxsgWyjdHnvckBqdiCqdX3hckBWQDePRzDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBPPy2PZXTHJIZwem2jdHnvckBi\nSncjCzJIhzeyCkeTDMR{1OWy:PUzDhcoFtgXOrcx?=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzZzNESxOEc,Ojd4MUS0NVQ9N2F-
U87MG	MYjBcpRqfHWvb4KgZZN{[Xl?				MoPWRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVUi3UWch[2WubIOgc5J1cG:2b4DpZ4FtdHlieHXuc4dz[W[2ZXSgbY4hUGG{bHHuJI52\GVibX;1d4Uh[nKjaX6gZZN{\XO\|ZXSgZZMhcW6mdXP0bY9vKG:oIIPsc5chfHWvb4Kg[5Jwf3SqIHH0JFUxKHWvb3yvb4ctKGm4IHHkcYlvcXO2ZYLl[EBwdmOnIHThbYx6KG[xcjC1JIRigXN?	NG\zPHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{[xOFQyPCd-Mke2NVQ1OTR:L3G+
U87MG	NG\scGdCdnSrdIXtc5Ih[XO\|YYm=				M2LTUmFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGW4O21IKGOnbHzzJI9zfGixdH;wbYNidGy7IIjlco9oemGodHXkJIlvKEijcnzhckBvfWSnIH3veZNmKGK{YXnuJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIH3veZNmKHO3co\peoFtKGG2IEWwJJVud2xxa3esJIl3KGGmbXnubZN1\XKnZDDvcoNmKGSjaXz5JIZweiB3IHThfZM>	NX7XOXQ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke2NVQ1OTRpPkK3OlE1PDF2PD;hQi=>
MDCK	NWjmfVl3S3m2b4TvfIlkcXS7IHHzd4F6		NF\LeGgzPCCqcoO=		NHHiRYZEgXSxdH;4bYNqfHliYXfhbY5{fCCPRFPLJINmdGy\|IHX4dJJme3OrbnegZ4Fz[m:waXOgZY5pgWS{YYPlJFkh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHnuZ5Vj[XSnZDDmc5IhOjRiaILzJI1m[XO3cnXkJIFnfGW{IEeg[IF6eyC3bnTldkBvd3Kvb4jpZ{Bkd26maYTpc44h[nlibXX0bJlt\W6nIHLseYUhe3SjaX7pcoch[mG\|ZXSgZ4xwdm:pZX7pZ{B{fXK4aY\hcEBie3OjeR?=	MnGwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd6MkO4O\|koRjJ5OEKzPFc6RC:jPh?=
MDCK	NHnz[mVEgXSxdH;4bYNqfHliYYPzZZk>		NESyeW8zPCCqcoO=		NV3kWnFrS3m2b4TvfIlkcXS7IHHnZYlve3RiTVTDT{Bk\WyuczDlfJBz\XO\|aX7nJINiemKxbnnjJIFvcHmmcnHz[UA6KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDpcoN2[mG2ZXSg[o9zKDJ2IHjyd{Bu\WG\|dYLl[EBi\nSncjC3JIRigXNidX7k[ZIhcHmyb4jpZ{Bkd26maYTpc44h[nlibXX0bJlt\W6nIHLseYUhe3SjaX7pcoch[mG\|ZXSgZ4xwdm:pZX7pZ{B{fXK4aY\hcEBie3OjeR?=	MmjTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd6MkO4O\|koRjJ5OEKzPFc6RC:jPh?=
NB-EBc1	NFPxVYhyUFSVIHHzd4F6				NXq5eFRTeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CMWVD[zFiY3XscJM>	M2jLSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
C6	NULQTohjS3m2b4TvfIlkcXS7IHHzd4F6		MY[0JIRigXN?		MV;FR\|UxKD1iMU[uOUDPxE1?	NFW2ZZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5OTBxJ{7DbGVOSkx:L3G+
U87	M1TBc2N6fG:2b4jpZ4l1gSCjc4PhfS=>		M4W5e\|czKGi{cx?=		M1\lWmlEPTBiPTCxPU4{QCEQvF2=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4NVAwLz6FaFXNRmw9N2F-
SNB19	MlPxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NXz3WJVEPyCmYYnz		Ml\aS2k2OCB;IEO1Mlch\|ryP	M2XzUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFgyOC9pPlPoSW1DVDxxYU6=
SNB19	Mki0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NGX5OGc4KGSjeYO=		NY\hXotCT0l3MDC9JFQ2NjZizszN	M3jSNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFgyOC9pPlPoSW1DVDxxYU6=
U373	NH3NTYxHfW6ldHnvckBie3OjeR?=	M2XC[\|ExOCC3TR?=	MoHEO\|IhcHK\|		NW\C[oVrUW6mdXP0bY9vKG:oIHTveYJt\SC\|dILhcoRm\CCGTlGgZpJm[WtiaX6g[Y1xfHlidnXjeI9zKHS{YX7z[oVkfGWmIHj1cYFvKFV\|N{OgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4h\2GvbXGtTFJCYCCuZY\lcEBifCBzMECgeW0h[W[2ZYKgO\|IhcHK\|IHL5JIZtd3diY4n0c41mfHK7	NEXRc3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5OTBxJ{7DbGVOSkx:L3G+
Glioma	NYLBT5NNSW62aYT1cY9zKGG\|c3H5				M{H1TWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JGhwdW9ic3HwbYVveyBqaIXtZY4qKEeuaX;tZUBk\WyuczD4[Y5w\3KjZoTl[EBqdiC2cnHud4dmdmmlIH3veZNmKGG\|c3Xzd4VlKGG\|IH3veZNmKHO3co\peoFt	MoK5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFExNyd-Q3jFUWJNRC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pERK / ERK / p-p38 / p38; PubMed: 24436439 Stem Cells Transl Med Cells were treated with TMZ (0.5 mM) time dependently, and Western blotting was used to analyze for phosphorylated ERK and p38 MAPK expression. DR5 / c-FLIP / Survivin / XIAP; PubMed: 24436439 Stem Cells Transl Med Western blot analysis showing expressions in DR5 and antiapoptotic proteins (c-FLIP, survivin, and XIAP) in glioma cells treated with increasing doses of TMZ (0–2 mM) for 24 hours.	24436439
Growth inhibition assay	Cell viability; PubMed: 25751281 Mol Pharm Distinct temozolomide-resistance for MGMT-expressing (SF767) and MGMT-negative (U87) GBM cells was assessed.	25751281
Immunofluorescence	Phalloidin / Phospho-H2A.X; PubMed: 27375225 Sci Rep Immunofluorescence analysis of the level of phospho-H2A.X in nucleus which can reflect DNA damage response increased significantly at day 6, peaked during days 7-10 and decreased significantly at day 12 after treatment temozolomide (200 μM). cleaved caspase-3; PubMed: 25663820 Cancer Cell Int Representative Photomicrographs of cleaved caspase-3 immunoreactivity in control (DMSO treated) and treated group of U87 cells. Base line immunofluorescence was detected in control group. Significant Increase in immunofluorescence is detected in all treated groups with the highest observed intensity in combination treatment group (NA-2 + TMZ).	27375225 25663820

In vivo

After a daily i.p. dose of 40 mg/kg for 5 consecutive days (days 1-5 after tumor transplant), methazolastone increases life-span by 86% in L-1210 and 22% in L-1210/BCNU. In L-1210/BCNU no effect is seen after 100 μM or 200 μM treatment; only 400 μM methazolastone produced an accumulation of cells in premitotic phase but much less than in L-1210. In L-1210/BCNU the maximum accumulation of cells in SL-G2-M is, after 48 hours-72 hours, approximately 30% as compared to 23% in untreated cells. Cells accumulates in SL-G2-M occurred too when L- 1210 leukemia-bearing mice are treated i.v. with methazola stone (40 mg/kg). No such effect is seen on L-1210/BCNU cells from mice given the same drug dose. ^[1]

Protocol

Cell Research:

^[1]

- Collapse

Cell lines: L-1210 and L-1210/BCNU cells
Concentrations: 0 μM -100 μM
Incubation Time: l hours
Method:
L-1210 and L-1210/BCNU cells are seeded at 0.2 × 10₄ cells/mL and incubated for 24 hours. The cultures are treated with Methazolastone for l hours at 37oC, then washed twice in PBS by centrifugation and resuspended in fresh medium. Controls and treated samples are diluted in fresh medium 1:4 at 48 hours and 1:2 at 96 hours. Using these dilutions cell concentrations throughout the experiments are between 3 × 10₅ and 8 × 10₅/mL. Control growth is logarithmic in this range.

(Only for Reference)

Animal Research:

^[1]

- Collapse

Animal Models: DBA/2 mice with L-1210 and L-1210/BCNU cells
Dosages: 40 mg/kg
Administration: Administered via i.v.
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	38 mg/mL (195.72 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Temozolomide (CCRG 81045) SDF

Molecular Weight	194.15
Formula	C₆H₆N₆O₂
CAS No.	85622-93-1
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	NSC 362856,TMZ
Smiles	CN1C(=O)N2C=NC(=C2N=N1)C(=O)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04091503	Not yet recruiting	Drug: Intranasal Modified Temozolomide	Glioma Malignant\|Gliosarcoma\|Astrocytoma of Brain	Center Trials & Treatment Europe	December 10 2019	Phase 1
NCT03932981	Recruiting	Drug: Temozolomide	Adult Brainstem Glioma	Assistance Publique - Hôpitaux de Paris	July 26 2019	Phase 2
NCT03463733	Recruiting	Drug: Hydroxyurea\|Drug: Temozolomide	Glioma\|Glioblastoma	M.E. van Linde\|Massachusetts General Hospital\|VU University Medical Center	March 2 2018	Phase 1
NCT02507232	Terminated	Device: NovoTTF-200A\|Drug: Temozolomide	Glioma	Santosh Kesari\|NovoCure Ltd.\|John Wayne Cancer Institute	April 17 2017	Early Phase 1
NCT02446704	Active not recruiting	Drug: Olaparib\|Drug: Temozolomide	Small Cell Lung Cancer	Massachusetts General Hospital\|AstraZeneca	September 2015	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Blasticidin S HCl ^New

Blasticidin S HCl is a nucleoside antibiotic isolated from Stretomyces girseochromogenes, and acts as a DNA and protein synthesis inhibitor, used to select transfected cells carrying bsr or BSD resistance genes.
Cisplatin (NSC 119875)

Cisplatin (NSC 119875, Cisplatinum, cis-diamminedichloroplatinum II, CDDP) is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells. Cisplatin activates ferroptosis and induces autophagy. Solutions are best fresh-prepared.

Features:One of the most widely used and most potent chemotherapeutic agents.
Gemcitabine (LY-188011) HCl

Gemcitabine (LY-188011, NSC 613327) HCl is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively.

Features:Gemcitabine has been used to treat pancreatic cancer and has demonstrated effective anti-tumor activity.
Oxaliplatin (NSC 266046)

Oxaliplatin (NSC 266046, L-OHP, Eloxatin) is a DNA alkylating agent that activates autophagy. Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells. DMF is recommended for dissolution. Solutions are best fresh-prepared.
Bleomycin (NSC125066) sulfate

Bleomycin Sulfate (NSC125066) is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.
Gemcitabine (LY-188011)

Gemcitabine (LY-188011, NSC 613327), a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy. Gemcitabine induces a potent p53-dependent apoptosis.
Fluorouracil (5-Fluorouracil, 5-FU)

Fluorouracil (5-Fluorouracil, 5-FU, NSC 19893) is a DNA/RNA synthesis inhibitor, which interrupts nucleotide synthetic by inhibiting thymidylate synthase (TS) in tumor cells. Fluorouracil induces apoptosis and can be used in the treatment of HIV.
Carboplatin (NSC 241240)

Carboplatin (NSC 241240, JM-8, CBDCA) is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells. Solutions are best fresh-prepared.

Features:A DNA synthesis inhibitor.

Choose Your Country or Region

By Signaling Pathways

By product type

Temozolomide (CCRG 81045)